Combinational Treatment of Imatinib and Allicin Synergistically Inhibits the Growth of BCR-ABL-Positive Leukemia and the Emergence of Drug-Resistant Cells

被引：0
|
作者：
Lim, Jamie
Kim, Jung-Hyun
Ahn, Eun-Young Erin
机构：
来源：
BLOOD | 2017年 / 130卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4992
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Efficacy of SCH66336, a farnesyl transferase inhibitor, in conjunction with imatinib against BCR-ABL-positive cells
    Nakajima, A
    Tauchi, T
    Sumi, M
    Bishop, WR
    Ohyashiki, K
    MOLECULAR CANCER THERAPEUTICS, 2003, 2 (03) : 219 - 224
  • [42] Dihydroartemisinin inhibits the Bcr/Abl oncogene at the mRNA level in chronic myeloid leukemia sensitive or resistant to imatinib
    Lee, Jun
    Shen, Peiqiang
    Zhang, Guobing
    Wu, Xiuhua
    Zhang, Xingguo
    BIOMEDICINE & PHARMACOTHERAPY, 2013, 67 (02) : 157 - 163
  • [43] Purging of peripheral blood stem cells yields BCR-ABL-negative autografts in patients with BCR-ABL-positive acute lymphoblastic leukemia
    Martin, H
    Atta, J
    Zumpe, P
    Eder, M
    Elsner, S
    Rode, C
    Wassmann, B
    Bruecher, J
    Hoelzer, D
    EXPERIMENTAL HEMATOLOGY, 1995, 23 (14) : 1612 - 1618
  • [44] BCR-ABL-POSITIVE AND BCR-ABL-NEGATIVE CLONOGENIC CELLS IN CML PATIENTS UNDERGOING LONG-TERM INTERFERON TREATMENT
    WANDL, UB
    BUTZLER, R
    NIEDERLE, N
    KLOKE, O
    MENGELKOCH, B
    BECHER, R
    SEEBER, S
    OPALKA, B
    LEUKEMIA, 1994, 8 (05) : 776 - 779
  • [45] Rituximab can be useful as treatment for minimal residual disease in bcr-abl-positive acute lymphoblastic leukemia
    Jándula, BM
    Nomdedeu, J
    Marín, P
    Vivancos, P
    BONE MARROW TRANSPLANTATION, 2001, 27 (02) : 225 - 227
  • [46] Rituximab can be useful as treatment for minimal residual disease in bcr-abl-positive acute lymphoblastic leukemia
    BM Jándula
    J Nomdedeu
    P Marín
    P Vivancos
    Bone Marrow Transplantation, 2001, 27 : 225 - 227
  • [47] Activity of the Aurora Kinase Inhibitor, MLN8237 (alisertib) Alone or in Combination with Ponatinib Against Imatinib-Resistant BCR-ABL-Positive Cells
    Okabe, Seiichi
    Tauchi, Tetsuzo
    Katagiri, Seiichiro
    Tanaka, Yuko
    Ohyashiki, Kazuma
    BLOOD, 2012, 120 (21)
  • [48] Combination of the ABL kinase inhibitor imatinib with the Janus kinase 2 inhibitor TG101348 for targeting residual BCR-ABL-positive cells
    Okabe, Seiichi
    Tauchi, Tetsuzo
    Katagiri, Seiichiro
    Tanaka, Yuko
    Ohyashiki, Kazuma
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2014, 7
  • [49] NK cells are dysfunctional in human chronic myelogenous leukemia before and on imatinib treatment and in BCR–ABL-positive mice
    C I-U Chen
    S Koschmieder
    L Kerstiens
    M Schemionek
    B Altvater
    S Pscherer
    J Gerss
    H T Maecker
    W E Berdel
    H Juergens
    P P Lee
    C Rossig
    Leukemia, 2012, 26 : 465 - 474
  • [50] Combination of the ABL kinase inhibitor imatinib with the Janus kinase 2 inhibitor TG101348 for targeting residual BCR-ABL-positive cells
    Seiichi Okabe
    Tetsuzo Tauchi
    Seiichiro Katagiri
    Yuko Tanaka
    Kazuma Ohyashiki
    Journal of Hematology & Oncology, 7
12345